Early biomarker dynamics are associated with treatment efficacy in a preclinical model of radiotherapy combines with a DNA damage response agent

Sygnature Discovery’s oncology team presents new data exploring DNA damage response (DDR) signalling and biomarker dynamics in A549 preclinical models. This work highlights how DDR inhibitors combined with radiotherapy can drive enhances efficacy and support mechanism-of-action studies in preclinical oncology.

Study Highlights

• Early biomarker profiling supports mechanistic insight
• Combination therapy improves in vivo efficacy
• Transcriptomic changes reveal treatment-specific effects

Advancing Preclinical Oncology Research

These findings support the use of DNA damage response-targeted strategies in combination with radiotherapy, highlighting the role of early biomarker profiling and gene expression analysis in guiding treatment development. The A549 model proved highly responsive to DDR modulation, offering a valuable tool for translation research.

Discovery our Oncology Expertise

Sygnature Discovery provides integrated support for preclinical oncology research, from in vitro pharmacology and efficacy models to biomarker discovery and transcriptomic analysis. Our experiences team can help you explore combination strategies and accelerate oncology drug discovery.